The Influence of Triclosan on Biomarkers of Cardiovascular Risk in Patients in the Cardiovascular and Periodontal Study (CAPS): A Randomized Controlled Trial

J Periodontol. 2015 Jul;86(7):847-55. doi: 10.1902/jop.2015.140716. Epub 2015 Mar 5.

Abstract

Background: Triclosan toothpaste is effective in controlling plaque and gingivitis and slowing progression of periodontitis; however, its influence on inflammatory biomarkers of cardiovascular disease (CVD), as well as on kidney and liver function, is unknown.

Methods: Patients recruited from the Cardiovascular Unit at Prince Charles Hospital, Brisbane, Australia, were randomized to triclosan (n = 193) or placebo (n = 190) groups and assessed for total cholesterol (TC), high density lipoprotein (HDL) and low density lipoprotein (LDL) cholesterol, triglycerides, C-reactive protein, erythrocyte sedimentation rate (ESR), hemoglobin, total white cell count (WCC), estimated glomerular filtration rate (eGFR), and liver function enzymes, annually for 5 years. A standard mixed model for each marker included group, sex, age, hypertension, diabetes, periodontal status, statin and anti-inflammatory drug use, and smoking as covariates. Changes in eGFR, WCC, and ESR were further analyzed using transition modeling.

Results: Triclosan toothpaste led to a greater decrease in TC (P = 0.03), LDL cholesterol (P = 0.04), and HDL cholesterol (P = 0.05) than placebo toothpaste. ESR increased at a slower rate in the triclosan group (P ≈ 0.06) and was less likely to increase and more likely to improve in males on statins but not anti-inflammatory drugs in the triclosan group versus the placebo group. Markov modeling of the binary response for eGFR (greater than or less than/equal to the baseline median value) showed that patients with diabetes in the placebo group were significantly (P ≈ 0.05) more likely to deteriorate than either patients with diabetes in the triclosan group or patients without diabetes in each group.

Conclusions: These data suggest that triclosan toothpaste may influence some inflammatory biomarkers of CVD, but not kidney or liver function. However, it is unclear if this influence is clinically significant.

Keywords: Biological markers; cardiovascular diseases; glomerular filtration rate; liver function tests; toothpastes; triclosan.

Publication types

  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • Anti-Infective Agents, Local / therapeutic use*
  • Biomarkers / analysis
  • Biomarkers / blood
  • Blood Sedimentation
  • C-Reactive Protein / analysis
  • Cardiovascular Diseases / blood*
  • Cholesterol / blood
  • Cholesterol, HDL / blood
  • Cholesterol, LDL / blood
  • Diabetes Complications
  • Double-Blind Method
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate / drug effects
  • Hemoglobins / analysis
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
  • Inflammation Mediators / analysis*
  • Inflammation Mediators / blood
  • Leukocyte Count
  • Male
  • Middle Aged
  • Placebos
  • Prospective Studies
  • Smoking
  • Toothpastes / therapeutic use*
  • Triclosan / therapeutic use*
  • Triglycerides / blood
  • Young Adult

Substances

  • Anti-Infective Agents, Local
  • Biomarkers
  • Cholesterol, HDL
  • Cholesterol, LDL
  • Hemoglobins
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Inflammation Mediators
  • Placebos
  • Toothpastes
  • Triglycerides
  • Triclosan
  • C-Reactive Protein
  • Cholesterol